In literature some studies suggested that in patients having solid malignancies poor prognosis is associated with vitamin D3 deficiency and replacement of vitamin D3 might have positive impact on prognosis. However, some of the results of the studies were against this suggestion. Therefore, in the current study we aimed to compare the clinical, pathological features and survival rates in patients with early breast cancer having regular vitamin D3 replacement or not.
In between October 2002 and October 2015, patients with early stage breast cancer were included in study population. The patients were divided into two groups according to their regular vitamin D3 replacement status. Vitamin D3 doses that the patients were receiving were calculated to increase the levels beyond 20 ng/mL (50 nmol/L). The patients with metastasis/relapse or second primary cancers were excluded.
In vitamin D3 and non-vitamin D3 group 92 and 2864 patients were included. Median follow up time was 60 (min:1- max:420) months. Mean age at time of diagnosis, rate of patients with postmenopause, T1 tumor and breast conserving surgery was significantly higher in vitamin D3 replacement group compared with non-vitamin D3 group (p
Regular vitamin D3 replacement therapy did not have effect on prognosis of patients with early breast cancer. Most of the postmenopausal and older aged patients with early breast cancer received vitamin D3 replacement most probably due to higher rate of osteoporosis in this aged patient group.
Clinical and pathological features of early breast cancer patients in vitamin D and non-vitamin D group
|Regular Vitamin D Replacement Group (n = 92) (%)||Non-Vitamin D Group (n = 2864) (%)||p|
|Mean Age||59 ± 11||49 ± 13||0.001|
|Invasive Histopathological Subtype Dutal Lobular Other||75 5.4 19.6||70 5 25||0.77|
|Grade 1 2 3||21 45.2 33.9||13 44.9 42.1||0.14|
|Body Mass Index 0-25 kg/m2 25-29.9 kg/m2 ≥30 kg/m2||34.7 37.3 28||35.4 36.6 28.1||0.98|
|Menapausal Status Premenopausal Perimenopausal Postmenopausal||22.8 8.7 68.5||49.8 7.1 43.1||0.001|
|Breast Surgery Mastectomy Breast Conserving||52.2 46.4||65.7 33.8||0.04|
|Estrogen Receptor Positive Negative||83.3 16.7||75.2 24.8||0.11|
|Progesterone Receptor Positive Negative||77.8 22.2||71.4 28.6||0.23|
|Her-2 Status Positive Negative||13.3 86.7||19.4 80.6||0.18|
|TNM Tumor Stage T1 T2 T3 T4||55.6 31.9 9.7 2.8||34.8 48.8 13.6 2.8||0.004|
|TNM Nodal Stage N0 N1 N2 N3||54.1 29.7 8.1 5.4||46 27.3 12.5 9.5||0.37|
Clinical trial identification
Legal entity responsible for the study
Ankara Numune Education and Research Hospital
All authors have declared no conflicts of interest.